{"id":4689,"date":"2016-02-01T20:36:21","date_gmt":"2016-02-02T01:36:21","guid":{"rendered":"http:\/\/www.khpi.org\/blog\/?p=4689"},"modified":"2016-02-11T09:52:56","modified_gmt":"2016-02-11T14:52:56","slug":"prescription-of-medicare-part-d-drugs-nationally-billions-left-on-the-table","status":"publish","type":"post","link":"http:\/\/www.khpi.org\/blog\/prescription-of-medicare-part-d-drugs-nationally-billions-left-on-the-table\/","title":{"rendered":"Prescription of Medicare Part-D Drugs Nationally: $Billions Left On The Table."},"content":{"rendered":"

In my last article<\/a>, I profiled the outpatient drugs prescribed to elderly and disabled Medicare beneficiaries of Kentucky in 2013. While I still had the analytical templates still in hand, I extended that analysis to all 50 states. Initial inspection\u00a0suggests that the relative pattern of drug prescription (and dispensing) is not greatly different than that of Kentucky. It may not be a surprise that we of the Bluegrass state consume relatively more hydrocodone, oxycodone, and gabapentin relative to other drugs, but less oral anticoagulant. A more granular comparison of Kentucky to the the the nation will require a different approach. This\u00a0Medicare data allows us to separate out the proportion of a given drug product that is dispensed and billed as a generic drug; a brand name drug; or as alternate preparations such as long-acting, tamper-resistant, or solid vs. liquid. The big take-away for me is that despite the supervision of Medicare\u2019s prescription drug programs by pharmacy benefit managers and others, much money is being spent in less than a medically defensible manner\u2013 or is frankly wasted. We as a nation are leaving billions of dollars on the table for pharmaceutical companies and those who market and distribute their products. I will summarize below national utilization and cost figures and make available an Excel file supporting the graphics.<\/p>\n

Background.<\/strong> I have been exploring the inaugural release of Medicare prescription drug utilization since its publication last spring. (We should get the numbers from calendar year 2014 in the next few months, but I have Medicaid 2014 in-hand and up-next!). The database does not include all Medicare beneficiaries, only those in Medicare Managed Care or in Medicare Part-D Drug plans, but that makes up a majority of bebefuicuarues. The proportions vary from state to state, but the Medicare programs covers eligible individuals over the age of 65, and some individuals who have been certified as disabled. There is a sizable proportion of individuals who are eligible for both Medicare and Medicaid for other reasons. I frankly do not at present have a good handle on the numbers of beneficiaries in these and other categories that may be included within the present data.<\/p>\n

Details from interactive graphics. (Follow Along)\"1-tot-no-rx-feb2016\"<\/a><\/strong>
\nFigure 1<\/a> and interactive online graphic Tab 1<\/a> present a TreeMap of all 3447 discrete drug products prescribed to these patients . The drugs comprise #14 billion prescriptions costing an aggregate of $103 billion paid by Medicare, other third-party payers, and by patients. Each rectangle in the chart tallies all forms of the underlying chemical ingredient and is further subdivided into generic and branded preparations. Some cells are filled nearly entirely with generic versions of a given drug drug such as the opioid combination hydrocodone\/acetaminophen or the anti-acid drug omeprazole. For other cells in 2013, only a brand name was available such as the purple anti-acid pill Nexium, the cholesterol drug Crestor, or the asthma\/COPD drug Advair. It is easy to spot which drugs have no generic competition because they are shaded a darker green indicating a high total cost to the body medical.<\/p>\n

How many do we really need?<\/strong>
\nAs we have seen, some 50-60 drugs make up more than half of the total prescriptions written and dispensed. At least 5 of these are opioids or opioid adjuvants subject to abuse \u2013 over 6% of all Medicare prescriptions right there! Three of the big-kahuna drugs (that I recognize) are for heartburn or symptoms of esophageal acid-reflux. There are too many sleeping pills or tranquilizers \u2013 certainly so for oldsters like me. I still can\u2019t believe so many people are taking thyroid hormone\u2014it\u2019s the number one prescribed drug.<\/p>\n

The online version<\/a> of Figure 1 is interactive and makes it easy to read the names and numbers behind even the smallest cell. In Figure 3<\/a> and online Tab 3, I present the same data, but only for drugs prescribed more than 2.5 Million times. The labels are easier to see, but some of the minority preparations dropped out of the sub-divided cells because they fail to meet this threshold. Therefore, cells are aggregated and labeled by generic drug name only<\/p>\n

If you can\u2019t afford it, it doesn\u2019t exist for you.\"2-total-drug-cost-feb2016\"<\/a><\/strong>
\nFigure 2<\/a> and online Tab 2 depict on the Total Cost of a given drug or branded product. The larger the cell or subdivision, the higher the total cost. For the most part, brand names take home the lions share of the 50-60 highest cost products. For some of these it is because they had no competition in 2013 such as Crestor, Nexium, Abilify, Spiriva, Colcrys, or Lyrica. Perhaps some of such brand name products offered a unique advantage that made the expenditure justifiable. In my own head, and based on what I can learn, I wonder if some brand name drugs are doing well for their makers largely because of the success of their marketing rather than any clear clinical advantage. For example, I am unaware of any clinical advantage of Nexium, the second costliest drug, over the well-tested and relatively inexpensive generic omeprazole. If all the prescribed Nexium had been paid for at the price of omeprazole, the public would have saved $2.4 Billion. Why does this not seem to bother anyone else enough to do something about it? Let\u2019s hear from an expert not on the payroll who is willing to justify the expense? A generic version of Nexium is now available, and in a rational world the demand for brand name Nexium would fade away. However, its manufacturer is systematically currently urging patients to ask their doctors to resist writing for the generic form. We shall see what happens. Figure 4<\/a> shows the same cost\u00a0numbers for drugs with a Total Cost greater than $250 million.<\/p>\n

Wasted!<\/strong>
\nIt is one thing to pay extra when you do not think you have any option, but how can it be justifiable to pay for a brand name drug when a perfectly acceptable generic alternative is already available? I have already written\u00a0about my favorite drug, L-Thyroxine, which literally rescued my life. Mousing over Tabs\u00a01 and 2<\/a> online easily identifies common and expensive drugs for which a generic form is available. For example, there are generic versions of Cymbalta, Synthroid, Seroquel SR, Lipitor, Vicodin, Diovan, Aricept, Lanoxin, and many many others. I will be the first to admit that I have never heard of, let alone used most of the drugs on this list. There may be intricacies related to the different preparations that are unknown to me. A generic version might not have even have been available for the entire year 2013. However, I can express an expert professional opinion that there is no meaningful advantage to taking the brand name non-steroidal anti-inflammatory drug Voltarin over its generic form diclofenac sodium. The fact that over 2 million prescriptions were written for Voltarin cost Medicare and its beneficiaries almost $100 million dollars more than necessary.<\/p>\n

Making the river flow backwards.<\/strong>
\nThere is a new wrinkle in brand name to generic conversions, and that is the reverse phenomena, from generic to brand name with subsequent sky-rocketing of price! The first I encountered this rip-off was with methotrexate in the 1990s. Generic methotrexate is a older drug used for cancer that proved to be the first drug than made any real difference in rheumatoid arthritis. Even better, it was generic, taken by mouth, and available in the smaller \u201cpediatric\u201d doses that we needed for arthritis. The icing on the cake was that it was the cheapest effective medicine available for that disease! \u00a0When it was shown- not by industry research- that the drug represented a breakthrough, the company abandoned its generic pills, renamed, and repackaged methotrexate, and jacked the price up to make it one of the most expensive! \u00a0We rheumatologists protested ineffectively. Ironically, administering high-priced drugs eventually turned rheumatology from one of the poorest paying medical specialties into one of the highest!<\/p>\n

The hijacking of generic drugs was a prominent news item this year when Martin Shkreli cornered the market on a standard anti-parasitic drug, pyrimethamine, and increased\u00a0its price from $13.50 a tablet to $750\u2013 raising the question of what parasite needed to be treated the most. As it happens, Mr. Shkreli was subsequently arrested on other business charges but I do not know what happened to the price of pyrimethamine since. Charging desperate people for more than their personal net worth is apparently the new standard for the pharmaceutical industry. We, though our elected officials, have given our approval to the strategy.<\/p>\n

I was reminded of generic-to-brand conversion\u00a0when I noted that Colcris, and not colchicine, was present in the TreeMap to the tune of 1.4 million prescriptions, $281 million dollars, at $203 per prescription. As it happens, colchicine is one of the very oldest known drugs in recorded history. It was mentioned by Hippocrates who employed many other untested remedies that survived for\u00a0centuries in that therapeutic limbo. It has been\u00a0used to treat acute gout (a form of arthritis), and then in more recent times, to prevent future attacks. It was highly toxic, only modestly effective, but cheap. When truly effective treatments for both acute and chronic gout came into use, colchicine fell into the background with limited indications. Nonetheless in a move that must have caught Mr. Shkreli\u2019s attention, one company took control of the product and jacked its price up such that for Medicare, Colcris is the 195th most prescribed outpatient drug and the 87th most costly of all several\u00a0thousands of drugs. To my knowledge colchicine as a generic drug is no longer available in this country. Flaming\u00a0this remarkable result is a flood of marketing through the \u201cContinuing Medical Education\u201d network focusing on the treatment of gout. You should assume that these three examples above represent only the smallest tip of the smallest iceberg of creative drug marketing.<\/p>\n

Which tweaks of a product add real value?<\/strong>
\nIn my opinion, there is not a lot of clinical judgement needed to substitute a generic drug for a brand name, at least for the kind of chemicals that make up the majority of existing drugs. Both classes have to pass Federal Food and Drug manufacturing standards. There are enough watchers of the process that my default inclination has always been to use generics when able. I am sure that some reader will be able to point out an example of a batch of a generic that failed to pass muster, but the same can be said about a host of brand names. Recalls happen all the time for both foreign-made and hometown drugs. I would like to think that if there was a meaningful difference between generic and brand name versions that my professional colleagues would shout it from the rooftops. I concede that the effects of some marketed drugs are so meager that only a statistician would be able to tell the difference in the first place. In that case, I have to ask why we are paying for that particular drug in the first place!<\/p>\n

However, many if not most of the alternatives to a regular generic version do not involve the active ingredient of the product. Such tweaks are often introduced as a strategy to maintain market share and to delay losing patent protection all at once. It is not possible to make a blanket statement that all such modifications of a given drug are without value. For example, for short-acting drugs it may be useful to have a slow-release formulation available to keep levels in the blood up or to avoid having to take as many pills in a day. For other drugs this would not be an issue. For some drugs and patients, a long-acting preparation might actually be harmful. (For example, some Medicare patients in this database are receiving long-acting sleeping pills. Not usually a good idea!) Some drugs,, like the opioids Opana and OxyContin, are sold as relatively tamper-resistant versions of their ingredients. Some alternatives are liquid, gel, or powder versions of the parent drug. Drugs are marketed as combination pills with other active ingredients, largely for convenience. (In general, combinations are to be discouraged. There needs to be a good reason to commit a given patient to fixed strengths of drugs. There are other downsides to combination drugs. For example, the incorporation of acetaminophen (Tylenol) in many other drugs has led to fatal overdoses of acetaminophen.) Of course, there are generic versions of many of the modifications above at much less expensive cost. For the distinctions as suggested above, clinical judgement plays an important role. One may fairly ask if we physicians and other prescribers are stepping up to the plate on our patients\u2019 behalf. Do we need an umpire? I would like to think not.<\/p>\n

What makes something worthwhile?<\/strong>
\nNonetheless, I fear that the procured benefits of all the heavily-marketed bell-and-whistle additions to basic generic drugs are not worth the often huge increases in their costs. I believe that a little more judicious application of clinical judgement would lead to much more efficient and cost effective medicine. This is not to say it would be easy. Value judgements are always present. For example, the single costliest drug for Medicare patients overall is Lantus, a manmade, genetically engineered human insulin costing us $2.5 Billion. It comes in two versions\u2013 one as a classic solution presumably in a little bottle that requires the use of additional insulin syringes; and Lantus Solostar which is packaged in\/with a self-administering injector. The two forms are being dispensed in nearly the same amounts but I do not know if using the Solostar version requires more individual prescriptions per patient. Self-injecting \u201cpens\u201d are especially useful for patients with limited vision, impaired manual dexterity, or limited cognitive abilities. The simple solution-in-a-bottle costs $285 per claim, and the second $355. Few would deny the value of making it easier or more reliable for people who need extra help. However, where and how do we make the distinctions between medically necessary, medically defensible, and patient convenience \u2013 and does it make a difference who is paying the bill? This whole example begs the fact that there are other and less expensive forms of human insulin available. Every drug in these lists list can be looked at, indeed should be looked at through these same lenses.<\/p>\n

The final \u00a0Tab 5 and Tab 6<\/a> associated\u00a0to today\u2019s project allow experts and the public alike to browse though the underlying data. Tab 5 Is an overlong bar graph of Total Cost for each prescribed drug presented in descending order of the Total Cost for the underlying parent drug. Is it broken out for each generic or brand name version. The bars are labeled with cost per prescription \u2013 what Medicare calls cost per claim. I invite the viewer to scroll down for a few pages to get a sense of the variation among products.<\/p>\n

Tab 6 is simply a basic table of the data underlying all of the figures presented above. It is probably unwieldly. For convenience, I also attach an Excel file<\/a> that allows the user to sort or otherwise manipulate the data further. Note that in the \u201cGeneric vs Brand\u201d tab of the Excel file, for a few drugs at the top of the list I calculated the amount that would be saved if a particular brand name or variant preparation were paid at the same price as the generic version. We can argue about whether even one penny should be spent on Nexium, but just working my way down the first few pages, I found millions of dollars in savings that I thought were no-brainers. To paraphrase former Senator Everett Dirksen of Illinois: \u201cA million here, a million there, and pretty soon you\u2019re talking about real money!\u201d<\/p>\n

Final words.<\/strong>
\nOf course its not just about the money spent, but the truism that medical resources saved in one place can be put to good use elsewhere. Surely there is no end to that need.<\/p>\n

My\u00a0next look at drugs will be at Medicaid utilization and expenditures in Kentucky, 2014. \u00a0Wait till you see what the newest high-cost drugs for hepatitis and drugs used to treat opioid drug addiction are doing to our budget! \u00a0I agree with Governor Bevin that Medicaid is unsustainable, but no more or less so than any\u00a0other segment of our fragmented\u00a0system of health care\u00a0\u2013\u00a0private or\u00a0public. Better to\u00a0grapple with the giants, to the advantage of all, rather than cast\u00a0the disadvantaged to the wolves.<\/p>\n

As always, if\u00a0I have made an error in fact, please help me correct it. \u00a0There is lots of room for inadvertent error in these masses of data.<\/p>\n

Peter Hasselbacher, MD
\nResident, KHPI
\nEmeritus Professor of Medicine, UofL
\nFeb 1, 2016<\/p>\n

Share this:<\/h3>